Cargando…
An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582361/ https://www.ncbi.nlm.nih.gov/pubmed/37859648 http://dx.doi.org/10.3389/fneur.2023.1209302 |
_version_ | 1785122313001238528 |
---|---|
author | Peng, Yong Yang, Huan Xue, Ya-hui Chen, Quan Jin, Hong Liu, Shu Yao, Shun-yu Du, Miao-qiao |
author_facet | Peng, Yong Yang, Huan Xue, Ya-hui Chen, Quan Jin, Hong Liu, Shu Yao, Shun-yu Du, Miao-qiao |
author_sort | Peng, Yong |
collection | PubMed |
description | Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities. |
format | Online Article Text |
id | pubmed-10582361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105823612023-10-19 An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes Peng, Yong Yang, Huan Xue, Ya-hui Chen, Quan Jin, Hong Liu, Shu Yao, Shun-yu Du, Miao-qiao Front Neurol Neurology Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582361/ /pubmed/37859648 http://dx.doi.org/10.3389/fneur.2023.1209302 Text en Copyright © 2023 Peng, Yang, Xue, Chen, Jin, Liu, Yao and Du. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Peng, Yong Yang, Huan Xue, Ya-hui Chen, Quan Jin, Hong Liu, Shu Yao, Shun-yu Du, Miao-qiao An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title_full | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title_fullStr | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title_full_unstemmed | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title_short | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
title_sort | update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582361/ https://www.ncbi.nlm.nih.gov/pubmed/37859648 http://dx.doi.org/10.3389/fneur.2023.1209302 |
work_keys_str_mv | AT pengyong anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yanghuan anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT xueyahui anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT chenquan anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT jinhong anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT liushu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yaoshunyu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT dumiaoqiao anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT pengyong updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yanghuan updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT xueyahui updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT chenquan updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT jinhong updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT liushu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yaoshunyu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT dumiaoqiao updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes |